Obesity Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 15 articles
Weight Loss Medications in 2026: GLP-1 Market Shift
Obesity rates in America by year: what the data shows
Eli Lilly raises 2026 revenue guidance on Mounjaro demand
Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications
Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors
Design Therapeutics' Friedreich's Ataxia Data and Vincentage's Obesity Results: A Strategic Analysis
Spotlight On: Four Things to Watch at ADA 2026
Medicare's GLP-1 Stance and UnitedHealthcare Lawsuit: Key Implications for Pharma
Hepatitis B Drug Developments and Lilly's Obesity Drug Returns
Kailera’s Three-Pronged Obesity Shot Shows Promise in Early Trial
Lilly's Triple-Acting Obesity Drug Achieves Phase 3 Trial Goals
Lilly's Triple Agonist: Leading the Charge in Obesity Treatment